Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/13802
Title: Novel action of the chalcone isoliquiritigenin as a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor: Potential therapy for cholera and polycystic kidney disease
Authors: Chatchai Muanprasat
Lalida Sirianant
Sunhapas Soodvilai
Ratchanaporn Chokchaisiri
Apichart Suksamrarn
Varanuj Chatsudthipong
Mahidol University
Ramkhamhaeng University
Keywords: Biochemistry, Genetics and Molecular Biology;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 8-Feb-2012
Citation: Journal of Pharmacological Sciences. Vol.118, No.1 (2012), 82-91
Abstract: Overstimulation of cAMP-activated Cl - secretion can cause secretory diarrhea. Isoliquiritigenin (ISLQ) is a plant-derived chalcone that has a wide range of biological activities. The present study thus aimed to investigate the effect of ISLQ on cAMP-activated Cl - secretion in human intestinal epithelium, especially the underlying mechanism and therapeutic application. Short-circuit current analysis of human intestinal epithelial (T84) cell monolayers revealed that ISLQ dose-dependently inhibited cAMP-activated Cl - secretion with an IC50 of approximately 20 μM. ISLQ had no effect on either basal short-circuit current or Ca 2+ -activated Cl - secretion. Apical Cl - current analysis of T84 cell monolayers indicated that ISLQ blocked mainly the cystic fibrosis transmembrane conductance regulator (CFTR) Cl - channels, but not other unidentified cAMPdependent Cl - channels. ISLQ did not affect intracellular cAMP levels or cell viability. ISLQ completely abolished the cholera toxin-induced transepithelial Cl - secretion in T84 cells and reduced the cholera toxin-induced intestinal fluid secretion in mouse closed loop models by 90%. Similarly, ISLQ completely inhibited the cAMP-activated apical Cl - current across monolayers of Madin-Darby Canine Kidney (MDCK) cells and retarded cyst growth in MDCK cyst models by 90%. This study reveals a novel action of ISLQ as a potent CFTR inhibitor with therapeutic potential for treatment of cholera and polycystic kidney disease. © The Japanese Pharmacological Society.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84856570690&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/13802
ISSN: 13478648
13478613
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.